High-impact clinical evidence, independently re-examined.The inconsistencies, gaps, and unsupported claims a rigorous read surfaces, before they shape a decision.
This is the live Rigor Showcase: high-impact randomized trials from NEJM, The Lancet, Nature Medicine, and The BMJ (2024–2026), each re-examined by Adcurare. It’s the centerpiece of a demo. We walk these findings with you, then run the same review on an asset of your own.
Browse the curated collections below.
Clinical Trials — Solid-Tumor Oncology
Randomized clinical trials in solid-tumor cancers (breast, lung, colorectal, prostate, renal, gastric, pancreatic, nasopharyngeal), from NEJM · Lancet · Nature Medicine · BMJ (2024–2026)
Signals in the original paper
Assets that later failed, retracted, or stalled — reviewed on the pivotal early paper, with retraction notices removed so the engine judges only the science.
See it on a real asset of your own
For BD, licensing, and diligence teams: request a demo to see how a pivotal trial, a data package, or a manuscript would be re-examined against a bar you set, then a scoped pilot when it’s a fit.